The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: A potential role for PTH(7-84)

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 6, 2010, Pages 2772-2780

  Wesseling Perry, Katherine ^a   Harkins, G Chris ^b   Wang, He Jing ^a   Elashoff, Robert ^a   Gales, Barbara ^a   Horwitz, Mara J ^c   Stewart, Andrew F ^c   Jüppner, Harald ^d   Salusky, Isidro B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Immutopics International   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PARATHYROID HORMONE[7-84]; PHOSPHORUS; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR; PARATHYROID HORMONE (7 84); PARATHYROID HORMONE (7-84); PEPTIDE FRAGMENT;

ADULT; ARTICLE; BONE BIOPSY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIALYSIS; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SKELETON; ADOLESCENT; BLOOD; BONE; BONE DEVELOPMENT; BONE MINERALIZATION; CHRONIC KIDNEY FAILURE; DRUG EFFECT; METABOLISM; PATHOLOGY; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; URINE;

ADOLESCENT; BONE AND BONES; BONE DEVELOPMENT; CALCIFICATION, PHYSIOLOGIC; CALCIUM; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PHOSPHORUS; RENAL DIALYSIS; YOUNG ADULT;

EID: 77954500243     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1909     Document Type: Article

References (52)

1. Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, Ikeda K, Fujimori A, Fukagawa M 2005 Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 101:c94-c99 (Pubitemid 41208897)
2. Kobayashi K, Imanishi Y, Miyauchi A, Onoda N, Kawata T, Tahara H, Goto H, Miki T, Ishimura E, Sugimoto T, Ishikawa T, Inaba M, Nishizawa Y 2006 Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol 154:93-99
3. Lorenz-Depiereux B, Bastepe M, Benet-Pagès A, Amyere M, Wagenstaller J, Müller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Jüppner H, Strom TM 2006 DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:1248-1250
4. Bilezikian JP 2003 Bone strength in primary hyperparathyroidism. Osteoporos Int 14(Suppl 5):S113-S115
5. 2 vitamin D. J Bone Miner Res 20:1792-1803
6. Ureña P, Mannstadt M, Hruby M, Ferreira A, Schmitt F, Silve C, Ardaillou R, Lacour B, Abou-Samra AB, Segre GV 1995 Parathyroidectomy does not prevent the renal PTH/PTHrP receptor downregulation in uremic rats. Kidney Int 47:1797-1805
7. Sherrard DJ 1986 Renal osteodystrophy. Semin Nephrol 6:56-67
8. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB 2003 Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272-2279 (Pubitemid 37449564)
9. Parisien M, Cosman F, Mellish RW, Schnitzer M, Nieves J, Silverberg SJ, Shane E, Kimmel D, Recker RR, Bilezikian JP 1995 Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J Bone Miner Res 10:1393-1399
10. Quarles LD, Lobaugh B, Murphy G 1992 Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145-150
11. Kuizon BD, Goodman WG, Jüppner H, Boechat I, Nelson P, Gales B, Salusky IB 1998 Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53:205-211 (Pubitemid 28066923)
12. National Kidney Foundation 2003 K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl 3):S1-S201
13. Massry SG, Coburn JW, Lee DB, Jowsey J, Kleeman CR 1973 Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. Ann Intern Med 78:357-364
14. Divieti P, John MR, Jüppner H, Bringhurst FR 2002 Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 143:171-176 (Pubitemid 34056416)
15. Krajisnik T, Björklund P, Marsell R, Ljunggren O, Akerström G, Jonsson KB, Westin G, Larsson TE 2007 Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125-131 (Pubitemid 350056006)
16. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J 2007 The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003-4008
17. Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF 2003 Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab 88:1603-1609
18. Horst RL, Reinhardt TA, Hollis BW 1990 Improved methodology for the analysis of plasma vitamin D metabolites. Kidney Int(Suppl 29):S28-S35
19. D'Amour P, Brossard JH, Rousseau L, Nguyen-Yamamoto L, Nassif E, Lazure C, Gauthier D, Lavigne JR, Zahradnik RJ 2005 Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 68:998-1007
20. Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, Wang HJ, Elashoff RM, Jüppner H 2003 Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 63:1801-1808
21. Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Jüppner H, Salusky IB 2009 Relationship between plasma FGF-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94:511-517
22. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
23. Salusky IB, Kuizon BD, Belin TR, Ramirez JA, Gales B, Segre GV, Goodman WG 1998 Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 54:907-914 (Pubitemid 28397408)
24. Sitara D 2007 Correlation among hyperphosphatemia, type II sodium phosphate transporter activity, and vitamin D metabolism in Fgf-23 null mice. Ann NY Acad Sci 1116:485-493
25. Thumfart J, Jung S, Amasheh S, Kramer S, Peters H, Sommer K, Biber J, Murer H, Meij I, Querfeld U, Wagner CA, Muller D 2008 Magnesium stimulates renal phosphate reabsorption. Am J Physiol Renal Physiol 295:F1126-F1133
26. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429-435
27. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T 2004 Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561-568
28. Sitara D, Razzaque MS, St-Arnaud R, Huang W, Taguchi T, Erben RG, Lanske B 2006 Genetic ablation of vitamin d activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol 169:2161-2170
29. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Jüppner H, Lanske B 2004 Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23:421-432
30. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH 1994 Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46:855-861 (Pubitemid 24272045)
31. Ureña P, Ferreira A, Morieux C, Drüeke T, de Vernejoul MC 1996 PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats. Nephrol Dial Transplant 11:2008-2016
32. Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T, Kurokawa K, Fukagawa M 2005 Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant 20:1904-1911
33. Kuwahara M, Inoshita S, Nakano Y, Terada Y, Takano Y, Sasaki S 2007 Expression of bone type 1 PTH receptor in rats with chronic renal failure. Clin Exp Nephrol 11:34-40
34. Sneddon WB, Syme CA, Bisello A, Magyar CE, Rochdi MD, Parent JL, Weinman EJ, Abou-Samra AB, Friedman PA 2003 Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EBP50). J Biol Chem 278:43787-43796
35. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D'Amour P 2001 Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 142:1386-1392
36. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A 2000 A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753-761 (Pubitemid 30620025)
37. Langub MC, Monier-Faugere MC, Wang G, Williams JP, Koszewski NJ, Malluche HH 2003 Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 144:1135-1138
38. Fasciotto BH, Gorr SU, DeFranco DJ, Levine MA, Cohn DV 1989 Pancreastatin, a presumed product of chromogranin-A (secretory protein-I) processing, inhibits secretion from porcine parathyroid cells in culture. Endocrinology 125:1617-1622
39. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692
40. Brown WW, Jüppner H, Langman CB, Price H, Farrow EG, White KE, McCormick KL 2009 Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. J Clin Endocrinol Metab 94:17-20
41. Barthel TK, Mathern DR, Whitfield GK, Haussler CA, Hopper 4th HA, Hsieh JC, Slater SA, Hsieh G, Kaczmarska M, Jurutka PW, Kolek OI, Ghishan FK, Haussler MR 2007 1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol 103:381-388
42. Yu X, Sabbagh Y, Davis SI, Demay MB, White KE 2005 Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 36:971-977
43. Kazama JJ, Sato F, Omori K, Hama H, Yamamoto S, Maruyama H, Narita I, Gejyo F, Yamashita T, Fukumoto S, Fukagawa M 2005 Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 67:1120-1125
44. Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M 2005 Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 67:1171-1178 (Pubitemid 41623344)
45. Antoniucci DM, Yamashita T, Portale AA 2006 Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 91:3144-3149
46. Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M 2006 Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 69:531-537
47. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H 1999 A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 84:4287-4290 (Pubitemid 30644232)
48. Martin KJ, Jüppner H, Sherrard DJ, Goodman WG, Kaplan MR, Nassar G, Campbell P, Curzi M, Charytan C, McCary LC, Guo MD, Turner SA, Bushinsky DA 2005 First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int 68:1236-1243
49. 3 and active vitamin D sterols. Pediatr Nephrol 24:1355-1361
50. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH 2001 Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 60:1460-1468
51. Mawad HW, Sawaya BP, Sarin R, Malluche HH 1999 Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol 52:160-166 (Pubitemid 29419470)
52. Sanchez CP, Salusky IB, Kuizon BD, Ramirez JA, Gales B, Ettenger RB, Goodman WG 1998 Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 53:1358-1364